IntelGenx strengthens board with additional appointments of Dr. Srinivas G. Rao and Frank Stegert
With the appointments, the size of the Company’s Board of Directors increased from six to eight.
SAINT LAURENT — On Aug. 4, IntelGenx Technologies Corp. announced the appointments of Srinivas (Srini) G. Rao, M.D., Ph.D. and Frank Stegert to its Board of Directors. The appointments of the two new directors were made pursuant to the previously disclosed purchaser rights agreement by and between the Company and ATAI Life Sciences AG. With the appointments, the size of the Company’s Board of Directors increased from six to eight.
Srinivas Rao has served as atai’s Chief Scientific Officer since April 2019 and Frank Stegert has served as atai’s Vice President, Investment Management and Operations since January 2021, having also served as a part-time consultant for atai prior to joining full-time. Dr. Rao has been assigned to the Compensation Committee of the Board and Mr. Stegert has been assigned to the Corporate Governance and Nominations Committee of the Board.
Each new director will serve until the 2022 annual meeting of the Corporation’s stockholders and until his successor is duly elected and qualified.
IntelGenx is a drug delivery company focused on the development and manufacturing of pharmaceutical films.
IntelGenx’s film technologies, including VersaFilm®, DisinteQ™, VetaFilm™ and transdermal VevaDerm™, allow for pharmaceutical products that address unmet medical needs. IntelGenx’s product pipeline purport to offer benefits to patients and physicians for many therapeutic conditions.